DOCSLIB.ORG

The Addiction Casebook This Page Intentionally Left Blank the Addiction Casebook

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Addiction Casebook This page intentionally left blank The Addiction Casebook Edited by Petros Levounis, M.D., M.A. Abigail J. Herron, D.O. Washington, DC London, England Note: The authors have worked to ensure that all information in this book is accurate at the time of publication and consistent with general psychiatric and medical standards, and that information concerning drug dosages, schedules, and routes of administration is accurate at the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice continue to advance, however, therapeutic standards may change. Moreover, specific situations may require a specific therapeutic response not included in this book. For these reasons and because human and mechanical errors sometimes occur, we rec- ommend that readers follow the advice of physicians directly involved in their care or the care of a member of their family. Books published by American Psychiatric Publishing (APP) represent the findings, con- clusions, and views of the individual authors and do not necessarily represent the poli- cies and opinions of APP or the American Psychiatric Association. If you would like to buy between 25 and 99 copies of this or any other American Psychi- atric Publishing title, you are eligible for a 20% discount; please contact Customer Ser- vice at [email protected] or 800-368-5777. If you wish to buy 100 or more copies of the same title, please e-mail us at [email protected] for a price quote. Copyright © 2014 American Psychiatric Association ALL RIGHTS RESERVED Manufactured in the United States of America on acid-free paper 18 17 16 15 14 5 4 3 2 1 First Edition Typeset in Trade Gothic and Minion Pro. American Psychiatric Publishing A Division of American Psychiatric Association 1000 Wilson Boulevard Arlington, VA 22209-3901 www.appi.org Library of Congress Cataloging-in-Publication Data The addiction casebook / [edited by] Petros Levounis, Abigail J. Herron. — First edition. p. ; cm. Includes bibliographical references and index. ISBN 978-1-58562-458-4 (pbk. : alk. paper) I. Levounis, Petros, editor of compilation. II. Herron, Abigail J., 1977– editor of com- pilation. III. American Psychiatric Association, issuing body. [DNLM: 1. Substance-Related Disorders—Case Reports. 2. Behavior, Addictive—Case Reports. WM 270] RC564.29 362.29--dc23 2013041547 British Library Cataloguing in Publication Data A CIP record is available from the British Library. Contents Contributors. .vii Preface. xi Part I. Introduction 1 DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. 3 Deborah S. Hasin, Ph.D. Erin M. Delker, M.P.H. Part II. Substance-Related Disorders 2 Alcohol: Conundrums of Co-occurring Disorders . .21 Faye Chao, M.D. 3 Caffeine: The Ins and Outs of Caffeine . .33 Gary P. Katzman, M.D. 4 Cannabis: A Natural Dilemma . .51 Timothy K. Brennan, M.D., M.P.H. Saadiq J. Bey, M.S.W., CASAC, ICADC 5 Hallucinogens: The Mind Field of Oswald: A Case of Hallucinogen Intoxication. .69 Elias Dakwar, M.D. 6 Inhalants: Just say N2O! . .91 Aykut Ozden, M.D. Shaneel Shah, M.D. 7 Opioids: Finding the Off Switch . .105 Glenn Occhiogrosso, M.D. Susan D. Whitley, M.D. 8 Sedatives, Hypnotics, or Anxiolytics: Sleepless Nights and the Magic Pills . .121 Claudie H. Jimenez, M.D., M.S. Abigail J. Herron, D.O. 9 Stimulants: Sex, Drugs, and Techno: Gay Men and Crystal Methamphetamine. .135 Joe Ruggiero, Ph.D. 10 Tobacco: From Social Norm to Modern Day Faux Pas. .151 Robbie Bahl, M.D. Petros Levounis, M.D., M.A. 11 Other (or Unknown) Substances: The Brave New World of Bath Salts and Other Synthetic Drugs . .163 Petros Levounis, M.D., M.A. Michael Ascher, M.D. Part III. Non-Substance-Related Disorder 12 Gambling: The Woman Who Became Tired of Trying to Predict the Future . .179 Mayumi Okuda, M.D. Silvia Bernardi, M.D. Carlos Blanco, M.D., Ph.D. Part IV. Condition for Further Study 13 Internet: Why Are Drug Addicts and People Who Use the Internet Both Called “Users?”. .191 Steven Joseph Lee, M.D. Index . .209 Contributors Michael Ascher, M.D. Fellow, Department of Psychiatry, Hospital of the University of Pennsylvania Addictions Fellowship Program, Philadelphia Veterans Administration Medi- cal Center, Philadelphia, Pennsylvania Robbie Bahl, M.D. Medical Director, Cedar Hill Hospital, Portland, Oregon Silvia Bernardi, M.D. Postdoctoral Residency Fellow, Department of Psychiatry, New York State Psy- chiatric Institute/Columbia University, New York, New York Saadiq J. Bey, M.S.W., CASAC, ICADC Research Assistant, AIDS Community Research Initiative of America, New York, New York Carlos Blanco, M.D., Ph.D. Professor of Clinical Psychiatry, Department of Psychiatry, New York State Psy- chiatric Institute/Columbia University, New York, New York Timothy K. Brennan, M.D., M.P.H. Associate Director, Fellowship in Addiction Medicine and Attending Physician, Addiction Institute of New York, New York, New York Faye Chao, M.D. Unit Chief, Inpatient Service, Addiction Institute of New York, St. Luke’s– Roosevelt Hospital Center, New York, New York Elias Dakwar, M.D. Assistant Professor of Clinical Psychiatry, Department of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York vii viii The Addiction Casebook Erin M. Delker, M.P.H. New York State Psychiatric Institute, New York, New York Deborah S. Hasin, Ph.D. Department of Psychiatry, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University; New York State Psychiatric Institute, New York, New York Abigail J. Herron, D.O. Director, Fellowship in Addiction Medicine, and Acting Medical Director, Ad- diction Institute of New York, St. Luke’s–Roosevelt Hospital Center, New York, New York Claudie H. Jimenez, M.D., M.S. Medical Director, Chemical Dependency Services, Harlem East Life Plan, New York, Ne w York Gary P. Katzman, M.D. Clinical Assistant Professor, Icahn School of Medicine at Mount Sinai, New York, Ne w York Steven Joseph Lee, M.D. Petros Levounis, M.D., M.A. Chair, Department of Psychiatry, Rutgers New Jersey Medical School, Newark, New Jersey Glenn Occhiogrosso, M.D. Unit Chief, Inpatient Detoxification Service, Kings County Hospital Center, Brooklyn, New York Mayumi Okuda, M.D. Postdoctoral Residency Fellow, Department of Psychiatry, New York State Psy- chiatric Institute/Columbia University, New York, New York Aykut Ozden, M.D. Clinical Assistant Professor of Psychiatry, Columbia University College of Phy- sicians and Surgeons; Director, Comprehensive Assessment Center, Depart- ment of Psychiatry, St. Luke’s–Roosevelt Hospital Center, New York, New York Contributors ix Joe Ruggiero, Ph.D. Assistant Clinical Director, Addiction Institute of New York; Director, Crystal Clear Project, St. Luke’s–Roosevelt Hospital Center, New York, New York Shaneel Shah, M.D. Child and Adolescent Psychiatry Fellow, Child and Adolescent Psychiatry Di- vision, Department of Psychiatry, St. Luke’s–Roosevelt Hospital Center, New York, New York Susan D. Whitley, M.D. Director of Chemical Dependency Services, Kings County Hospital Center; Clinical Assistant Professor of Psychiatry and Family Medicine, State University of New York Downstate, Brooklyn, New York x The Addiction Casebook Disclosure of Interests The following contributors have indicated that they have no financial interests or other affiliations that represent or could appear to represent a competing interest with their contributions to this book: Michael Ascher, M.D.; Robbie Bahl, M.D., Saadiq J. Bey, M.S.W., CASAC, ICADC; Timothy K. Brennan, M.D., M.P.H.; Faye Chao, M.D.; Elias Dakwar, M.D.; Deborah S. Hasin, Ph.D.; Abigail J. Herron, D.O.; Claudie H. Jimenez, M.D., M.S.; Gary P. Katzman, M.D.; Steven Joseph Lee, M.D.; Petros Levounis, M.D., M.A.; Mayumi Okuda, M.D.; Aykut Ozden, M.D.; Joe Ruggiero, Ph.D.; Shaneel Shah, M.D.; Susan D. Whitley, M.D. Preface FEW illnesses come with more stigma and misunderstanding than the addic- tions. The majority of our patients who have substance use disorders are not properly diagnosed and do not receive adequate medical care. Yet working with these patients is both scientifically fascinating and immensely rewarding. Although this casebook is far from complete in covering the breadth and depth of our current knowledge in the diagnosis and treatment of substance use and other addictive disorders, we hope that it will provide the fundamental tools for working with the substance-using patient in the hospital, the clinic, and the community. The book begins with an introductory chapter that outlines the progression of our thinking in terms of psychiatric diagnosis as we move from DSM-IV-TR (American Psychiatric Association 2000) to DSM-5 (American Psychiatric Asso- ciation 2013). This first chapter is different in tone and format from the rest of the book and explains the reasoning behind the change in criteria sets and the broad- ening of the concept of addictive disorders to include the behavioral addictions. It is followed by 12 case studies with assessment tools and treatment recommenda- tions. Each case study introduces a patient with an addiction DSM-5 diagnosis (except for the last chapter on problematic Internet use) followed by a discussion that illustrates common ways of working with addicted patients. An additional goal of the book is to show clinicians who have little experience in this area the in- tersection of addiction with other psychiatric diagnoses. This casebook has been a collaboration of three generations of addiction specialists. We have invited our peers, as well as our mentors and our students, to join us in formulating the most salient ideas and suggestions that we have found helpful for treating people who are dealing with substance use and other addictions. We are indebted to them for their great insights and clinical wisdom.
Recommended publications
  • |||GET||| a Dictionary for Dreamers 1St Edition

    |||GET||| a Dictionary for Dreamers 1St Edition

    A DICTIONARY FOR DREAMERS 1ST EDITION DOWNLOAD FREE Tom Chetwynd | 9781351695961 | | | | | ISBN 13: 9780446798259 Le Guin's book, The Lathe of Heaventhe protagonist finds that his "effective" dreams can retroactively change reality. Jung expanded on Freud's idea that dream content relates to the dreamer's unconscious desires. Tarnow's theory is a reworking of Freud's theory of dreams in which Freud's unconscious is replaced with the long-term memory system and Freud's A Dictionary for Dreamers 1st edition Work" describes the structure of long-term memory. Tom Chetwynd has isolated for the first time the rich meanings of over archetypal symbols from the indiscriminate mass of dream material, and rated the likelihoods of the various possible interpretation in each case. During REM sleep, however, the communication between the neocortex and the hippocampus is disrupted by a high ACh level. Similarly, research scientistsmathematicians and physicists have developed new ideas by daydreaming about their subject areas. Amsterdam: John Benjamins. In A Dictionary for Dreamers 1st edition such as SpellboundThe Manchurian Candidateand Inceptionthe protagonists must extract vital clues from surreal dreams. The brain synthesizes and interprets these activities; for example, changes in the physical environment such as temperature and humidity, or physical stimuli such as ejaculation, and attempts to create meaning from these signals, result in dreaming. Those that appear adaptive are retained, while those that appear maladaptive are culled. The activation-synthesis theory hypothesizes that the peculiar nature of dreams is attributed to certain parts of the brain trying to piece together a story out of what is essentially bizarre information.
  • Tobacco & Cannabis

    Tobacco & Cannabis

    TOBACCO & CANNABIS: THE EVOLUTION OF PERTINENT RULES & REGULATIONS AND SUBSEQUENT FINANCIAL RAMIFICATIONS by Virginia Palmer Yerger Avisto A thesis submitted to the faculty of The University of Mississippi in partial fulfillment of the requirements of the Sally McDonnell Barksdale Honors College. Oxford May 2016 Approved by _________________________ Advisor: Dr. Bonnie Van Ness _________________________ Reader: Dr. Travis Box _________________________ Reader: Dr. Dwight Frink © 2016 Virginia Palmer Yerger Avisto ALL RIGHTS RESERVED ii I would like to dedicate my thesis to all family members who encouraged me to apply to the Honors College and acted as my cheerleaders throughout the entire process. Peter Avisto Virginia Avisto Harrison Avisto Gingia Yerger Swan Yerger Patricia Avisto Uno Avisto iii ABSTRACT PALMER AVISTO: Tobacco & Cannabis: The Evolution of Pertinent Rules & Regulations and Subsequent Financial Ramifications (Under the direction of Dr. Bonnie Van Ness) My thesis will discuss the evolution of the regulations surrounding tobacco and cannabis and the subsequent financial ramifications later posed on pertaining companies and the industries themselves. I will also briefly discuss the evolution of tobacco advertisements and the introduction of e-cigarettes into the tobacco market. Concerning newly legalized cannabis stores, I will discuss the struggle to acquire financial tools, the state-Federal disagreement, and proposed solutions to those issues. Both having been deemed “public enemy number one,” I will compare marijuana and tobacco regarding health effects, profitability after new laws, and their overall economic profitability for the country. I researched and summarized all pertinent regulations for the two industries and analyzed the available annual reports for the major tobacco companies.
  • Exploring the Effects of Galantamine Paired with Meditation and Dream

    Exploring the Effects of Galantamine Paired with Meditation and Dream

    Consciousness and Cognition 63 (2018) 74–88 Contents lists available at ScienceDirect Consciousness and Cognition journal homepage: www.elsevier.com/locate/concog Full Length Article Exploring the effects of galantamine paired with meditation and dream reliving on recalled dreams: Toward an integrated protocol T for lucid dream induction and nightmare resolution ⁎ Gregory Sparrowa, , Ryan Hurdb, Ralph Carlsonc, Ana Molinac a Dept. of Counseling, University of Texas Rio Grande Valley, 1201 W. University Dr., Edinburg, TX 78539, United States b Dept. of Psychology, John F. Kennedy University, Orinda, CA, United States c Dept. of Educational Psychology, 1201 W. University Dr., University of Texas Rio Grande Valley, Edinburg, TX 78539, United States ARTICLE INFO ABSTRACT Keywords: An experimental home study examined the impact of a pre-sleep protocol for enhancing self- Lucid dream awareness, lucidity, and responsiveness in dreams. It included ingesting the cholinesterase in- Trauma resolution hibitor galantamine––which is widely reported to increase the frequency of lucid dreaming––- Meditation prior to engaging in middle-of-the-night meditation and the imaginary reliving of a distressing Dream reliving dream while exercising new responses. Thirty-five participants completed an eight-night study, Galantamine which included pre- and post-baseline nights and six conditions: waking for 40 min before re- turning to bed, called Wake-Back-to-Bed (WBTB); Wake-Back-to-Bed plus placebo (WBTB + P); Wake-Back-to-Bed plus galantamine (WBTB + G); meditation and dream reliving (MDR); medi- tation and dream reliving plus placebo (MDR + P); and meditation and dream reliving plus galantamine (MDR + G). The outcome measures included lucidity, reflectiveness, interactive behavior, role change, constructive action, and fear and threat, as measured by the participants’ self-ratings.
  • The Impact of Cannabis Access Laws on Opioid Prescribing

    The Impact of Cannabis Access Laws on Opioid Prescribing

    Journal of Health Economics 69 (2020) 102273 Contents lists available at ScienceDirect Journal of Health Economics j ournal homepage: www.elsevier.com/locate/econbase The impact of cannabis access laws on opioid prescribing a,∗ b c Benjamin J. McMichael , R. Lawrence Van Horn , W. Kip Viscusi a Assistant Professor of Law, University of Alabama School of Law, Box 870382, 101 Paul W. Bryant Drive East, Tuscaloosa, AL, 35487, United States b Associate Professor of Management and Law, Executive Director of Health Affairs, Owen Graduate School of Management, Vanderbilt University, 401 21st Avenue South, Nashville, TN, 37203, United States c University Distinguished Professor of Law, Economics, and Management, Vanderbilt University Law School. 131 21st Avenue South, Nashville, TN, 37203, United States a r a t i c l e i n f o b s t r a c t Article history: While recent research has shown that cannabis access laws can reduce the use of prescrip- Received 5 October 2018 tion opioids, the effect of these laws on opioid use is not well understood for all dimensions Received in revised form 17 July 2019 of use and for the general United States population. Analyzing a dataset of over 1.5 bil- Accepted 7 December 2019 lion individual opioid prescriptions between 2011 and 2018, which were aggregated to the Available online 14 December 2019 individual provider-year level, we find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 11.8 and 4.2 JEL classification: percent, respectively. These laws also reduce the total days’ supply of opioids prescribed, I180 the total number of patients receiving opioids, and the probability a provider prescribes K19 any opioids net of any offsetting effects.
  • A Phenomenological Analysis of the Subjective Experience Elicited by Ibogaine in the Context of a Drug Dependence Treatment

    A Phenomenological Analysis of the Subjective Experience Elicited by Ibogaine in the Context of a Drug Dependence Treatment

    ORIGINAL ARTICLE Journal of Psychedelic Studies 1(2), pp. 74–83 (2017) DOI: 10.1556/2054.01.2017.007 First published online August 25, 2017 A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment EDUARDO EKMAN SCHENBERG1*, MARIA ANGÉLICA DE CASTRO COMIS1, JOÃO FELIPE MOREL ALEXANDRE2, LUÍS FERNANDO TÓFOLI3, BRUNO DANIEL RASMUSSEN CHAVES1 and DARTIU XAVIER DA SILVEIRA4 1Instituto Plantando Consciência, São Paulo, Brazil 2Centro de Matemática, Computação e Cognição, Universidade Federal do ABC (UFABC), Santo André, Brazil 3Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil 4Departamento de Psiquiatria, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil (Received: September 5, 2016; accepted: June 22, 2017) Objective: This report documents the phenomenology of the subjective experiences of 22 patients with substance- related disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods: Participants underwent a one-to-one semi-structured interview exploring the subjective effects of ibogaine. We employed interpretative phenomenological analysis to identify relevant phenomenological categories, including physical sensations, perceptual (visual, auditory, and olfactory), emotional, cognitive, and spiritual. Participants also compared ibogaine with other drugs used in life, including psychedelics like ayahuasca, psilocybin mushrooms, and lysergic acid diethylamide. Results: The findings reveal that the subjective experience with ibogaine has similarities with other psychedelic substances, but also important differences. These include very strong and unpleasant physical effects as well as, at least in this patient population, a very difficult and challenging experience. Conclusions: Overall, the descriptions involve heightened memory retrieval, specially related to drug abuse and the perception of one’s own future with or without drug use.
  • The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming Within a Large Database of Psychoactive Substance Reports

    The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming Within a Large Database of Psychoactive Substance Reports

    ORIGINAL RESEARCH published: 22 January 2018 doi: 10.3389/fnins.2018.00007 The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports Camila Sanz 1, Federico Zamberlan 1, Earth Erowid 2, Fire Erowid 2 and Enzo Tagliazucchi 1,3* 1 Departamento de Física, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Erowid Center, Grass Valley, CA, United States, 3 Brain and Spine Institute, Paris, France Ever since the modern rediscovery of psychedelic substances by Western society, Edited by: several authors have independently proposed that their effects bear a high resemblance Rick Strassman, to the dreams and dreamlike experiences occurring naturally during the sleep-wake University of New Mexico School of cycle. Recent studies in humans have provided neurophysiological evidence supporting Medicine, United States this hypothesis. However, a rigorous comparative analysis of the phenomenology (“what Reviewed by: Matthias E. Liechti, it feels like” to experience these states) is currently lacking. We investigated the semantic University Hospital Basel, Switzerland similarity between a large number of subjective reports of psychoactive substances and Michael Kometer, University of Zurich, Switzerland reports of high/low lucidity dreams, and found that the highest-ranking substance in *Correspondence: terms of the similarity to high lucidity dreams was the serotonergic psychedelic lysergic Enzo Tagliazucchi acid diethylamide (LSD), whereas the highest-ranking in terms of the similarity to dreams [email protected] of low lucidity were plants of the Datura genus, rich in deliriant tropane alkaloids. Specialty section: Conversely, sedatives, stimulants, antipsychotics, and antidepressants comprised most This article was submitted to of the lowest-ranking substances.
  • Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

    Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

    molecules Review Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming 1,2,* , Milan Scheidegger 3 , Dario Dornbierer 3, Mikael Palner 4,5,6 , Boris B. Quednow 3,7 and Chantal Martin-Soelch 8 1 Department of Nuclear Medicine, Bern University Hospital, CH-3010 Bern, Switzerland 2 School of Psychology and Counselling, Queensland University of Technology, Brisbane 4059, Australia 3 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, CH-8032 Zurich, Switzerland; [email protected] (M.S.); [email protected] (D.D.); [email protected] (B.B.Q.) 4 Odense Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; [email protected] 5 Department of Nuclear Medicine, Odense University Hospital, DK-5000 Odense, Denmark 6 Neurobiology Research Unit, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark 7 Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, CH-8058 Zurich, Switzerland 8 Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Hallucinogens are a loosely defined group of compounds including LSD, N,N- dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), Citation: Cumming, P.; Scheidegger, which can evoke intense visual and emotional experiences. We are witnessing a renaissance of re- M.; Dornbierer, D.; Palner, M.; search interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. Quednow, B.B.; Martin-Soelch, C. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and Molecular and Functional Imaging ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or Studies of Psychedelic Drug Action in single photon emission computer tomography (SPECT).
  • Conscious Dreaming and Controlled Hallucinations

    Conscious Dreaming and Controlled Hallucinations

    Conscious Dreaming and Controlled Hallucinations Claude de Contrecoeur ([email protected]) This work is dedicated to my cherished Hiroé Aquasaca, from Kasoukabé, Tôquiô, who gave me the inspiration to share it with other exoreal people. Had I not met her, you would very probably not be reading this study! It is also dedicated to another cherished Chinese girlfriend of mine: Patanîe Pongpatchamnanouàte from Souqsaouate, Bângkoc (this work is also dedicated to my dear friend Cyrano de Bergerac, a brillant Hiroé Aquasaca thinker of the 17th century). Both are my Patanîe Pongpatchamnanouàte inspiration to inform you about this important work. What we call Amour (love) is an extraordinary hallucination, and from such beautiful hallucinations things can be born into the exogenous reality ... like what you are going to read. Alors chères Patanîe et Hiroé un jour vous ferez partie de l'Histoire! For whoever authentically knows about Conscious Dreams, money, glory, recognition and similar bla, bla, bla are nonsense! This is the main reason why I did not bother to put my work into a book (as Dr A.Hobson from Harvard repeatedly suggested to me!). Maybe this will be done in the future if people manifest their interest in this topic. Otherwise? There's no use in me wasting my time if only a few people are interested! Reading this, you will clearly understand why!! ● Conscious dreams ● How to achieve conscious dreams ● MHVs are like tunnels linking MCV boxes! ● The new alphabetisation of mankind ● There are two ways to penetrate a conscious dream ● What to do in a conscious dream ● About different states of consciousness and "new" concepts ● Different states of consciousness are generated via the mutual interactions of the attenuator, DRP and SBEM ● Why does dreaming exist? ● Oneiric Maps (Les Cartes oniriques) ● What is the rôle of DMT in the CNS? ● Continuity and discontinuity of consciousness ● The illusioned consciousness: towards an understanding of consciousness ● Déjà Vu is the lowest state of Illusion ● When a Naked Woman becomes transformed into a Banana..
  • The Nightmare Free

    The Nightmare Free

    FREE THE NIGHTMARE PDF lars Kepler | 608 pages | 03 Jan 2013 | HarperCollins Publishers | 9780007414505 | English | London, United Kingdom The Nightmare - Wikipedia The Nightmare By Henry Fuseli. Regarded as one of the The Nightmare Paintings Ever. For the meaning of other celebrated masterpieces, please see: Famous Paintings Analyzed One of the most innovative Romantic artists of his day, the Swiss-born Johann Heinrich Henry Fuseli - son of the The Nightmare Johann Caspar Fussli - developed an early talent for drawing before moving to London The Nightmare at the age of Here, encouraged by Joshua Reynolds who was shortly to be elected the first president of the newly formed Royal Academy of ArtsFuseli took up painting. This led him to spend most of the s in Italy, studying the figure painting of Michelangelo which became a major influence on his art. Other influences included 16th-century Mannerism and literary sources, notably Shakespeare. Later appointed a professor of painting at the Royal Academy, he became one of the best English painters of the eighteenth century and was buried in St Paul's Cathedral. Like his The Nightmare contemporary William BlakeFuseli's strength as a painter lies in his imaginative intensity, and The Nightmare - which he sold for 20 guineas - remains his greatest and most baffling masterpiece. Overlooked after his death, Fuseli was 'rediscovered' by 20th-century Expressionists and Surrealists who greatly admired his creativity. Painted shortly after his return from Italy, The Nightmare was first shown to the public in The Nightmare the annual exhibition of the Royal Academy. An instant success, it established Fuseli's reputation as one of the most creative artists in London.
  • The Forensic Identification of Marijuana: Suspicion, Moral Danger, and the Creation Of

    The Forensic Identification of Marijuana: Suspicion, Moral Danger, and the Creation Of

    Title: The Forensic Identification of Marijuana: Suspicion, Moral Danger, and the Creation of Non-Psychoactive THC Author: Aaron Roussell* Running Head: “Marijuana Identification” Abstract: Federal and state laws present marijuana as a dangerous substance requiring coercive control and forbid private citizens from possessing, selling, or growing it. Possession cases brought under these laws depend on a forensic confirmation of taxonomic identity as Cannabis sativa to establish and successfully prosecute a case. Hemp Industries Association v. DEA (2003), a recent federal appeals court ruling, is at odds with this forensic process. American citizens may legally possess and even consume a similar substance — hemp and its derivatives — which can be made into such everyday objects as clothing, rope, and food products. Yet these two plants are both Cannabis sativa and differ only in physical structure and degree of natural tetrahydrocannabinol (THC). Synthetic THC is also a medically prescribed substance, which introduces further confusion into the legal standing of cannabis. Finally, *Department of Criminology, Law & Society, University of California, Irvine. Address correspondence to Aaron Roussell, Department of Criminology, Law & Society, University of California, Irvine, Social Ecology II, Irvine, CA 92697; email: [email protected]. 949-943-9860 Thanks to Professors Simon Cole, Justin Richland, Michael Clegg, and Dr. Fred Whitehurst for their direct or indirect contributions and assistance, as well as Akhila Ananth, Vivek Mittal, and Trish Goforth for their help with paper drafts and the editorial staff of the Albany Law Journal of Science and Technology for their superb efforts to improve the final version. Mistakes and weaknesses herein are entirely in spite of their efforts and remain the sole dominion of the author.
  • Hallucinogens As Treatment? Preliminary Data with Ketamine

    Hallucinogens As Treatment? Preliminary Data with Ketamine

    Hallucinogens as Treatment? Preliminary Data with Ketamine Elias Dakwar, MD Columbia University College of Physicians and Surgeons 19 October, 2017 Disclosures Elias Dakwar has received funding from NIDA and NIAAA. He has no conflicts of interest to report. Overview How might hallucinogens work as treatment? Why might ketamine work as a treatment? By any other name Deliriant Entheogen Hallucinogen Imaginant Oneirogen Phanarothyme Phantasticant Psychedelic Psychotomimetic A diverse group Indoles - d-lysergic-acid (LSD), dimethyltryptamine (DMT), harmaline, ibogaine, psilocybin, Dissociative Anesthetics - ketamine, PCP Phenethylamines -mescaline, 2-CB, DOM, MDA, MDMA Others - nitrous oxide, salvia divinorum, THC, fly agaric mushroom Effects Produce in a time-limited manner non-ordinary experiences comparable to: trance psychosis ecstasy dreaming mystical experience Ancient Uses Ritual Divination Initiation Pleasure Healing Witchcraft Protection/fortification Modern Uses Classical hallucinogens were investigated in the 1950s through the early ’70s in various settings. psychiatric treatment quality of life improvement investigations of consciousness criminal justice warfare “Psychedelic” and “Psycholytic” treatment models Concern over recreational use obscured promising clinical data and clinical research was largely aborted due to criminalization in 1973. But has recently resumed via private foundation funding Set and Setting A valuable heuristic for optimizing benefits, minimizing risks Set: the recipient’s expectations, past experiences,
  • Full Programme As

    Full Programme As

    Notes Contents Contents 1 Abstracts (Alphabetically by Presenter) 4-20 Programme (Friday) 22-24 Programme (Saturday) 25-28 Programme (Sunday) 29-32 Underdog - THE AFTER PARTY - All Days 33 Films 34-35 Performers 37 Speaker Bios 38-46 Artists Bios 47-48 Sponsors 52 Contributors 53 Media Partners 53 Acknowledgements 50-51 University Map 55 Venue Map 56 General Info 57 Notes 57-60 Break Times Friday Saturday & Sunday 11:00 - 11:30 Break 11:00 - 11:30 Break 13:30 - 14:30 Lunch 13:00 - 14:30 Lunch Artwork: maze & brain logos by Blue Firth, front cover by Judith Way, inside back cover 16:30 - 17:00 Break 16:30 - 17:00 Break by Cameron Adams, back cover background by Dave King, booklet design and layout Giorgos Mitropapas Programme Design by Giorgos Mitropapas - www.gmitropapas.com 60 1 Notes 2 59 General Info Transport There is transport info on the website http://breakingconvention.co.uk/location/ and London transport info is available from http://www.t! .gov.uk Catering Regrettably there are no refreshments available in the conference centre during the weekend but you can bring your own and there are numerous cafés around outside the university within easy walking distance (5-10 mins) and we have reasonably long breaks. The university refectory is also open in the adjacent building (Queen Mary) and is serving cold snacks/meals and hot/cold drinks, but on Saturday & Sunday only! If you are a tea or co" ee addict, like me, you might consider bringing a ! ask of the black stu" to keep your blood-ca" eine levels high or be prepared for a small stroll to get your # x.